Etyka Osrodek Badan Klinicznych Tomasz Pesta S.K.A. — Clinical Trial Site

39 Registered trials

12 Currently recruiting

Organisation

Etyka Osrodek Badan Klinicznych Tomasz Pesta S.K.A.

Location

Olsztyn, Poland

Identifier

ORG-100042137

Address

Ul. 1 Maja 13 C, 10-117, Poland

Departments

-
.
#417: ETYKA Ośrodek Badań Klinicznych
#7804: Rheumatology
40796: ETYKA Osrodek Badan Klinicznych
cardiology department
Dermatology
ETYKA OSRODEK BADAN KLINICZNYCH
Etyka Osrodek Badan Klinicznych Tomasz Pesta S.K.A.
N/A
NA
Not applicable
site name:ETYKA Ośrodek Badań Klinicznych

Clinical trials at this site (39)

Search interface

A phase III, randomised, double-blind, multicentre study comparing the efficacy, safety, and immunogenicity of proposed tocilizumab biosimil… Not authorised

2022-501361-44-00 Adult patients of either gender with active moderate to 5
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (P… Pending

2025-522471-28-00 psoriatic arthritis (PsA) 5
A Phase 3, Long-Term Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Zasocitinib in Subjects with Active Pso… Pending

2025-522586-30-00 Psoriatic Arthritis 5
Long-Term Safety Study of Deucravacitinib versus Ustekinumab in Participants with Psoriasis (PRAGMATYK) Recruiting

2023-503766-24-00 Moderate to Severe Plaque Psoriasis 11 2026-05-26
A Long-Term Extension Study of IMVT-1402 in Adult Patients With Graves' Disease Recruiting

2025-524001-33-00 Graves’ Disease 4 2026-05-22
A study to learn if bimekizumab given in different ways is safe and moves similarly throughout the body over time in adults Recruiting

2025-522782-30-00 CCI 3 2026-04-07
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis Recruiting

2025-520721-21-00 Rheumatoid Arthritis 4 2025-10-20
A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with… Recruiting

2024-513965-38-01 Sjögren's Disease 5 2025-06-16
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Pso… Recruiting

2024-515706-77-00 Moderate to Severe Plaque Psoriasis 5 2025-05-08
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the E… Recruiting

2023-507039-39-00 Moderate to Severe Plaque Psoriasis 5 2024-03-22
A Phase 3 program evaluating the effect of filgotinib in subjects with active axial spondyloarthritis Recruiting

2022-501354-10-01 axial spondyloarthritis 5 2023-06-21
A study to learn about the effectiveness and safety of different doses of JNJ-88545223 in people with active psoriatic arthritis Recruiting

2025-523141-10-00 Active Psoriatic Arthritis 4 2026-03-20
A Phase 2b Study to Assess the Efficacy and Safety of IMVT-1402 in Patients With Graves' Disease Recruiting

2025-521920-31-00 Graves’ Disease 4 2025-11-21
A Phase 3 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib (BMS-986165) in Adolescent Participants with Moder… Recruiting

2023-506296-97-00 Moderate to Severe Plaque Psoriasis 5 2025-10-28
A Study of Zasocitinib in Adults with Psoriatic Arthritis Who Have Not Taken Biologic Medicines Recruiting

2024-513111-27-00 Psoriatic Arthritis 5 2025-06-26
A Study of the Efficacy and Safety of JNJ-77242113 in Biologic-naïve Participants with Active Psoriatic Arthritis Ended

2023-509239-19-00 Active Psoriatic Arthritis 5 2025-04-03
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active… Ended

2024-516213-20-00 Psoriatic arthritis 5 2025-03-25
A study to learn how well bimekizumab works and how safe it is in adults with psoriatic arthritis Ended

2024-511738-11-00 Psoriatic arthritis 5 2024-12-18
A Clinical Study in which patients with acne vulgaris will receive a new topical drug. The safety and efficacy of the drug will be tested. Ended

2023-510341-19-00 acne vulgaris 5 2024-11-14
A Clinical Study in which patients with acne vulgaris will receive a new topical drug for long term. The safety and efficacy of the drug wil… Ended

2023-510342-24-00 Acne vulgaris 5 2024-11-11
REIMAGINE 5: A research study to see how much CagriSema (1.0 mg once weekly) lowers blood sugar and body weight compared to tirzepatide (5 m… Ended

2023-509600-15-00 Type 2 Diabetes 5 2024-10-18
MLS-101-901: An Open-Label Extension Study to Assess the Long-Term Safety, Efficacy, and Tolerability of Lorundrostat in Subjects with Hyper… Ended

2023-508670-28-00 Hypertension 5 2024-08-26
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic … Ended

2023-503655-10-00 Systemic Lupus Erythematosus (SLE). 5 2023-11-20
An Open-Label Extension Study to Evaluate Long Term Safety and Efficacy of Tildrakizumab in Patients with Psoriatic Arthritis. Ended

2022-501480-41-00 Psoriatic Arthritis 5 2023-04-06